Alector's AL002 misses primary endpoint in Alzheimer's trial. BofA downgrades stock, cuts price target, and highlights near-term challenges.
BofA downgraded Alector (ALEC) to Underperform from Neutral with a price target of $1, down from $9.Don't Miss our Black Friday Offers:Unlock ...
Alector Inc (ALEC) stock saw a decline, ending the day at $2.16 which represents a decrease of $-0.04 or -1.82% from the prior close of $2.2. The stock opened at $2.27 and touched a low of $2.06 ...
As previously reported, BofA downgraded Alector (ALEC) to Underperform from Neutral with a price target of $1, down from $9, after ALOO2 missed ...
AbbVie Inc. (NYSE:ABBV) revealed topline results from its pivotal Phase 3 TEMPO-2 trial, which evaluated investigational ...
As previously reported, BofA downgraded Alector (ALEC) to Underperform from Neutral with a price target of $1, down from $9, after ALOO2 missed the mark in its Phase 2 Alzheimer’s trial.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...
Alector had a negative net margin of 257.54% and a negative return on equity of 108.77%. The business had revenue of $15.34 million during the quarter, compared to analyst estimates of $16.33 million.
Despite the trial's failure, Alector secured a $50 million credit facility from Hercules Capital (NYSE:HTGC) Inc., aimed at supporting ongoing research and development efforts. The company ...
Arnon Rosenthal, the Chief Executive Officer of Alector, Inc. (NASDAQ:ALEC), recently reported the sale of 52,172 shares of the company's common stock, totaling approximately $131,442. The sale ...
As of 12:34:05 PM EST. Market Open. Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal.